

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3139702

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
AVAC PHARMA LIMITED	09/11/2014

**RECEIVING PARTY DATA**

<b>Name:</b>	CHRONTECH PHARMA AB
<b>Street Address:</b>	HÄLSOVÄGEN 7
<b>City:</b>	HUDDINGE
<b>State/Country:</b>	SWEDEN
<b>Postal Code:</b>	SE-141 57

**PROPERTY NUMBERS Total: 25**

Property Type	Number
Patent Number:	6680059
Patent Number:	7261883
Patent Number:	7244422
Patent Number:	6858590
Patent Number:	7241440
Patent Number:	7244715
Patent Number:	6960569
Patent Number:	7439347
Patent Number:	7226912
Patent Number:	7022830
Patent Number:	7307066
Patent Number:	7223743
Patent Number:	7638499
Patent Number:	7943149
Patent Number:	8163547
Patent Number:	8163712
Patent Number:	8158602
Patent Number:	7566812
Patent Number:	7968697
Patent Number:	8071561
Patent Number:	8258275

PATENT

Property Type	Number
Patent Number:	8445663
Application Number:	13178373
Application Number:	13856271
Application Number:	13441305

**CORRESPONDENCE DATA**

**Fax Number:** (949)760-9502

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 949-760-0404

**Email:** efilling@knobbe.com

**Correspondent Name:** ERIC S. FURMAN

**Address Line 1:** KNOBBE MARTENS OLSON & BEAR LLP

**Address Line 2:** 2040 MAIN STREET, 14TH FLOOR

**Address Line 4:** IRVINE, CALIFORNIA 92614

<b>ATTORNEY DOCKET NUMBER:</b>	TRIEPEP
<b>NAME OF SUBMITTER:</b>	ERIC FURMAN
<b>SIGNATURE:</b>	/Eric Furman/
<b>DATE SIGNED:</b>	12/09/2014

**Total Attachments: 5**

source=Assignment-AVAC-Chrontech#page1.tif

source=Assignment-AVAC-Chrontech#page2.tif

source=Assignment-AVAC-Chrontech#page3.tif

source=Assignment-AVAC-Chrontech#page4.tif

source=Assignment-AVAC-Chrontech#page5.tif

**ASSIGNMENT**


WHEREAS, AVAC PHARMA LIMITED, an Irish company having offices at 88 Harcourt Street, Dublin 2, Ireland (hereinafter "ASSIGNOR") represents and warrants that it is the sole owner of the entire right, title, and interest to the patents and patent applications set forth in Schedule 1 ("the Patents").


WHEREAS, CHRONTECH PHARMA AB, a Swedish company having offices at Hälsövägen 7, Huddinge, SE-141 57, Sweden (hereinafter "ASSIGNEE"), desires to purchase the entire right, title, and interest in and to the inventions disclosed in the Patents.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby further acknowledges that it has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer, unto ASSIGNEE, its successors, legal representatives, and assigns, the entire right, title, and interest to the said Patents and all National Patents that may be granted thereon, and all divisions, continuations, continuations-in-part, designs, and extensions thereof, and all rights of priority under International Conventions and any applications for Letters Patent that may hereafter be filed stemming from said Patents in any country; and ASSIGNOR hereby authorizes and requests any Official of any country, whose duty it is to issue National Patents stemming from the Patents, to issue all Letters Patent to ASSIGNEE, its successors, legal representatives, and assigns, in accordance with the terms of this Agreement.

ASSIGNOR does hereby sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the said Patent before or after issuance;

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will communicate to said ASSIGNEE, its successors, legal representatives, and assigns, any facts known to ASSIGNOR respecting the Patents, and testify in any legal proceeding, assist in the preparation of any divisional applications relating to the Patents, sign all lawful papers, authorize the filing of and execute and make all rightful oaths and/or declarations in connection with the Patents and any divisional applications stemming therefrom, and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives, and assigns, to obtain and enforce proper patent protection for the Patents in all countries.

\_\_\_\_\_  
CHRONTECH PHARMA AB  
By:   
Name Printed: Anders Vahlne  
Title: CEO  
Date: 23<sup>RD</sup> October 2014

\_\_\_\_\_  
AVAC PHARMA LIMITED  
By:   
Name Printed: STUART MC DONNELL  
Title: DIRECTOR  
Date: 11 SEPTEMBER 2014

## Schedule 1

Case Number	Title	Country	App. No. or Patent No.
AVAC.23AUSC1	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	6,680,059
AVAC.23AUSC2	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	7,261,883
AVAC.23AUSC2C	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	7,244,422
AVAC.23AUS2	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	6,858,590
AVAC.23AUS2C1	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	7,241,440
AVAC.23AUS2CC	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	7,244,715
AVAC.023QAT	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Austria	1311289
AVAC.023QAU	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Australia	2001292151
AVAC.023QBE	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Belgium	1311289
AVAC.023QCA	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Canada	2419418
AVAC.023QCH	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Switzerland	1311289
AVAC.023QCN	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	China	ZL01815071.3
AVAC.023QDE	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Germany	60130999
AVAC.023QES	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Spain	1311289
AVAC.023QFR	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	France	1311289
AVAC.023QGB	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Great Britain	1311289
AVAC.023QHKG2	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Hong Kong	11113602
AVAC.023QIE	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Ireland	1311289
AVAC.023QIT	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Italy	1311289
AVAC.023QJP	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Japan	5175417
AVAC.023QKR	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Republic of Korea (South)	10-0801123

AVAC.023QRAU	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Australia	2006203358
TRIEP.023QRCH	HCVNS3/4A ENCODING NUCLEIC ACID	Switzerland	1947185
TRIEP.023QRDE	HCVNS3/4A ENCODING NUCLEIC ACID	Germany	1947185
TRIEP.023QRES	HCVNS3/4A ENCODING NUCLEIC ACID	Spain	1947185
TRIEP.023QRFR	HCVNS3/4A ENCODING NUCLEIC ACID	France	1947185
TRIEP.023QRGB	HCVNS3/4A ENCODING NUCLEIC ACID	United Kingdom	1947185
TRIEP.023QRIE	HCVNS3/4A ENCODING NUCLEIC ACID	Ireland	1947185
TRIEP.023QRIT	HCVNS3/4A ENCODING NUCLEIC ACID	Italy	1947185
AVAC.028AUS	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE	USA	6,960,569
AVAC.028C1	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,439,347
AVAC.028C1C1	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,226,912
AVAC.028CP1	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,022,830
AVAC.028CP1C1	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,307,066
AVAC.28CP1C1C	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,223,743
AVAC.28CPC1C2	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,638,499
AVAC.28CPC1C3	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,943,149
AVAC.28CPC1C4	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	USA	8,163,547
AVAC.28CPC1C5	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	USA	8,163,712
AVAC.28CPC1C6	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	USA	8,158,602
AVAC.28P1C8	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	USA	13/441305

AVAC.028QAU	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Australia	2003290385
AVAC.028QCA	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Canada	2506820
AVAC.028QCN	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	China	200380109208.7
AVAC.028QAT	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Austria	1567190
AVAC.028QBE	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Belgium	1567190
AVAC.028QCH	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Switzerland / Liechtenstein	1567190
AVAC.028QDE	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Germany	1567190
AVAC.028QES	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Spain	1567190
AVAC.028QFR	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	France	1567190
AVAC.028QGB	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	United Kingdom	1567190
AVAC.028QIE	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Ireland	1567190
AVAC.028QIT	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Italy	1567190
AVAC.028QHK	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Hong Kong	06102404.0
AVAC.028QJP	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Japan	4660195
AVAC.028QKR	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE	Korea	10-1144642
AVAC.070NP	TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HCV) AND IDENTIFICATION OF HCV THERAPEUTICS	USA	7,566,812

AVAC.070VDE	TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HCV) AND IDENTIFICATION OF HCV THERAPEUTICS	Germany	1781690
AVAC.070VFR	TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HCV) AND IDENTIFICATION OF HCV THERAPEUTICS	France	1781690
AVAC.070VGB	TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HCV) AND IDENTIFICATION OF HCV THERAPEUTICS	United Kingdom	1781690
TRIPEP.080NP	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,968,697
AVAC.111A	IMMUNOGEN PLATFORM	USA	8,071,561
AVAC.111C1	IMMUNOGEN PLATFORM	USA	13/178,373
AVAC.111CP1C1	IMMUNOGEN PLATFORM	USA	8,258,275
AVAC.111VEP	IMMUNOGEN PLATFORM	EP	08827413.9
AVAC.116NP	COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE	USA	8,445,663
AVAC.116C1	COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE	USA	13/856271
AVAC.116EP	COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE	Europe	10710625.4
AVAC.116HK	CODON-OPTIMISED HEPATITIS B VIRUS CORE ANTIGEN	Hong Kong	12105381.2
AVAC.116IN	CODON-OPTIMISED HEPATITIS B VIRUS CORE ANTIGEN	India	6734/DELNP/2011

\*\*\*\*\*

7731642.1

5

SMD

PATENT

RECORDED: 12/09/2014

REEL: 034442 FRAME: 0823